Sentences with phrase «from generic drug companies»

In its May 13, 2014 Statement, the Bureau stated that «product life - cycle management strategies in the pharmaceutical sector are not inherently anti-competitive... However, life - cycle management strategies that are designed to impede competition from generic drug companies, such as product switching strategies, may cause significant harm to competition.»

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Another bright spot could be the slowing in the decline of U.S. generic drug prices, according to report from Credit Suisse, citing data from health information company IQVIA.

(Next, Mylan wants to buy Ireland - based Perrigo (PRGO) to further transform itself from a generic prescription drug maker to a more diversified healthcare company, though Perrigo has so far rebuffed its overtures.)

Given its areas of specialization, Gilead wouldn't benefit as much from consolidation as, say, a generic - drug company would, but it still faces pricing pressure: To appease Medicaid and other insurers, Gilead is already steeply discounting its hep - C drugs, which can cost more than $ 80,000 for a 12 - week course.

The generic drug company tripled the discount patients can receive on the cost of EpiPen to $ 300, up from the maximum $ 100 Mylan had previously offered with the use of its special «savings card.»

Allergan would also bolster Pfizer's «innovative» (i.e. brand - name) drug business, which it internally separated from its slower - growing «established» (i.e. generic and non-patented) drug division in 2014, further signaling that it may be planning to split into two different companies altogether.

In the letter, the antitrust bureau chief for New York Attorney General Eric Schneiderman asked Shkreli to contact the office «immediately» to respond to concerns that the company's sales practices were intended to deter generic pharmaceutical firms from creating alternatives to the drug.

FORTUNE — On Jan. 23, the FDA dropped a heavy hammer on the Indian generic drug giant Ranbaxy Laboratories, announcing it will restrict imports from the company's manufacturing plant in Toansa, India.

The divestment would complete the company's gradual shift away from its original focus on generic drugs and nuclear imaging toward branded specialty pharmaceuticals, which now comprise the bulk of its revenues.

Those companies had sought approval from the U.S. Food and Drug Administration to sell a generic version of Ampyra.

So, the company can still benefit from generic drug offerings.

Doctors, clinic staff and pharmacists, Malani says, can help patients identify options from drug companies that might reduce costs by reducing copayments or overall price, and recommend generic equivalents when available.

Attempting to determine dosage amounts of a drug according to the generic recommendation that «this will work for everybody» from a company or business that is interested more in making a sale than in the health of the population is counterproductive to the initial impetus behind taking the medication in the first place.